Rapid decline of anti-hepatitis C virus (HCV) antibodies following early treatment of incident HCV infections in HIV-infected men who have sex with men.

OBJECTIVES: Following clearance of incident hepatitis C virus (HCV) infections, HCV antibody levels may decline, resulting in seroreversion. It is unclear to what extent HCV antibody level trajectories differ between patients with treatment-induced sustained virological response (SVR), those with spontaneous clearance and those with untreated replicating HCV infection. We investigated HCV antibody level dynamics in HIV-infected MSM with different clinical outcomes. METHODS: We investigated anti-HCV antibody level dynamics following an incident HCV infection in 67 HIV-infected men who have sex with men (MSM) with different clinical outcomes: SVR (n = 33), spontaneous clearance (n = 12), and untreated replicating infection (n = 22). Antibody levels were measured at the time of HCV diagnosis, and at yearly intervals for 3 years thereafter. RESULTS: At baseline, median HCV antibody levels were similar in the three groups: 13.4, 13.8 and 13.5 sample to cut-off (S/CO) for SVR, spontaneous clearance and untreated infection, respectively. Over 3 years of follow-up, SVR was associated with a more pronounced decrease in anti-HCV levels compared with spontaneous clearance and untreated infection [median decline 71% [interquartile range (IQR: 43-87%), 38% (IQR: 29-60%) and 12% (IQR: 9-22%), respectively; P < 0.001]. Seroreversions occurred in five of 33 (15%) patients with SVR and in one of 12 (8%) with spontaneous clearance. A shorter delay between time of infection and treatment start correlated with higher rates of decline in antibody levels. Seven patients experienced a reinfection. CONCLUSIONS: Treatment-induced HCV clearance was associated with a more pronounced decline in anti-HCV antibody levels and with higher rates of seroreversion compared with spontaneous clearance or untreated replicating HCV infection among HIV-infected MSM with incident HCV infections. Rapid clearance of HCV RNA following early HCV treatment might impair the development of persistent antibody titres.

On the potential of a short-term intensive intervention to interrupt HCV transmission in HIV-positive men who have sex with men: A mathematical modelling study.

Increasing access to direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) infection and decelerating the rise in high-risk behaviour over the next decade could curb the HCV epidemic among HIV-positive men who have sex with men (MSM). We investigated if similar outcomes would be achieved by short-term intensive interventions like the Swiss-HCVree-trial. We used a HCV transmission model emulating two 12-months intensive interventions combining risk counselling with (i) universal DAA treatment (pangenotypic intervention) and (ii) DAA treatment for HCV genotypes 1 and 4 (replicating the Swiss-HCVree-trial). To capture potential changes outside intensive interventions, we varied time from HCV infection to treatment in clinical routine and overall high-risk behaviour among HIV-positive MSM. Simulated prevalence dropped from 5.5% in 2016 to ≤2.0% over the intervention period (June/2016-May/2017) with the pangenotypic intervention, and to ≤3.6% with the Swiss-HCVree-trial. Assuming time to treatment in clinical routine reflected reimbursement restrictions (METAVIR ≥F2, 16.9 years) and stable high-risk behaviour in the overall MSM population, prevalence in 2025 reached 13.1% without intensive intervention, 11.1% with the pangenotypic intervention and 11.8% with the Swiss-HCVree-trial. If time to treatment in clinical routine was 2 years, prevalence in 2025 declined to 4.8% without intensive intervention, to 2.8% with the pangenotypic intervention, and to 3.5% with the Swiss-HCVree-trial. In this scenario, the pangenotypic intervention and the Swiss-HCVree-trial reduced cumulative (2016-2025) treatment episodes by 36% and 24%, respectively. Therefore, intensive interventions could reduce future HCV treatment costs and boost the benefits of long-term efforts to prevent high-risk behaviour and to reduce treatment delay. But if after intensive interventions treatment is deferred until F2, short-term benefits of intensive interventions would dissipate in the long term.

Multiresistant Shigella species isolated from pediatric patients with acute diarrheal disease.

A total of 57 strains of Shigella (36 S sonnei, 21 S flexneri), isolated from children with acute diarrheal disease who presented for treatment at the Andes University Hospital, Merida, Venezuela, from June 1993 to June 1995, were tested for their susceptibility to trimethoprim, sulfamethoxazole, ampicillin, cefamandole, ceftriaxone, streptomycin, fleroxacin, and nalidixic acid, by the agar dilution method. Twenty-seven strains (75%) of S sonnei and eight strains of S flexneri (38.1%) isolates showed high-level resistance to trimethoprim (MIC90 > 1024 microg/mL), which was also associated with other resistance patterns. The most common resistant phenotype associated with trimethoprim-resistance among S sonnei isolates was sulfamethoxazole-streptomycin (63%); among S flexneri isolates, it was sulfamethoxazole-ampicillin-streptomycin (87.5%). Individual resistance was only observed for ampicillin, mainly in four isolates of S flexneri, and in one isolate of S sonnei. Most Shigella strains were resistant to three or more antimicrobial agents. These results confirmed that multiresistant strains of Shigella are present in Merida, and emphasize the importance to maintain these under surveillance in order to assess local susceptibility patterns and empiric therapy.

[Comparative study of 4 methods for identifying species of the genus Aeromonas]. / Estudio comparativo de 4 métodos para la identificación de especies del género aeromonas.

It is given an explanation of the results obtained with the following methods: AEROKEY II, AEROKEY II + Abbot's scheme, Api 20 NE, and the Biolog System. The study was conducted with 38 strains of Aeromonas isolated from children under 5 with acute diarrheal disease (ADD). The AEROKEY II + Abbot's scheme proved to be the best identification method.

Especies de aeromonas asociadas a diarrea: características microbiológicas y clínicas / Species of aeromonas associated a diarrhea: characteristic microbiological and clinical

Para estudiar las características microbiológicas y clínicas de Aeromonas sp. asociada a Enfermedad Diarreica Aguda (EDA) se analizaron, desde junio de 1993 1 diciembre de 1994, 397 muestras de heces de niños menores de cinco años con EDA y 121 asintomáticos. Fueron aisladas en una frecuencia de 11,8 y 5,8 por ciento en los casos de EDA y control, respectivamente. A.hydrophila y A.caviae fueron las especies más aisladas en ambos casos. Como patógenos únicos se encontraron en un 38,3 por ciento, y asociados en un 61,7 por ciento. La presentación del cuadro clínico fue 50 por ciento de tipo disentérico: 33,33 por ciento de tipo secretorio y 16.66 por ciento de tipo indeterminado. El mejor medio de cultivo fue el DNA-ampicilina. Se obtuvo un 1 por ciento con producción de H2S y un 5 por ciento fermentadoras de la lactosa. En las cepas se detectó por lo menos dos de las enzimas estudiadas; en base a esto, existe una importante circulación de este género con capacidad de producir EDA